Abstract: An adjuvant for transdermal or transmucosal administration which comprises at least one substance selected from an aliphatic alcohol, a free fatty acid and a fatty acid derivative but does not contain a substance represented by the following formula: wherein R3 and R4 may together form a cyclic ring, and R1 and R2 independently represent an alkyl side chain having 1 to 16 carbon atoms.

Abstract: There is provided a wound healing composition which comprises at least one oxidant, at least one photoactivator capable of activating the oxidant and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin in association with a pharmaceutically acceptable carrier. In addition, a method of topically treating wounds using at least one oxidant and at least one photoactivator capable of activating the oxidant followed by illumination of said photosensitizer is disclosed.

Abstract: The present invention provides methods, compositions, systems, and kits comprising core-satellite nanocomposites useful for photothermal and/or MRI applications (e.g., tumor treatment and/or imaging). In certain embodiments, the core-satellite nanocomposites comprise: i) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core, and ii) at least one satellite component attached to, or absorbed to, the biocompatible coating. In some embodiments, the nanoparticle core and satellite component are composed of near-infrared photothermal agent material and/or MRI contrast agent material. In further embodiments, the satellite component is additionally or alternatively composed of near-infrared optical dye material.

Abstract: The invention combines light and compounds to accelerate healing. This photobiolocical treatment system activates cells at a molecular level after the ingestion or application of nitric oxide activators then shining light on afflicted area, resulting in faster recovery. Isolated wavelengths of monochromatic biostimulatory light and vasodilating compounds are independently are known to increase and accelerated cellular metabolism and promote faster than normal recovery. Utilizing both simultaneously activates a synergistic biological effect on cells at a molecular level speeding the injured biological living tissue recovery time of patients.

Abstract: A biodegradable battery is provided. The battery includes an anode comprising a material including an inner surface and an outer surface, wherein electrochemical oxidation of the anode material results in the formation of a reaction product that is substantially non-toxic and a cathode comprising a material including an inner surface and an outer surface, the inner surface of the cathode being in direct physical contact with the inner surface of the anode, wherein electrochemical reduction of the cathode material results in the formation of a reaction product that is substantially non-toxic, and wherein the cathode material presents a larger standard reduction potential than the anode material.

Abstract: The present invention provides a method whereby a drug can be conveniently injected into the living body, without sticking a needle, from a device that is not in contact with the living body, and a device therefor. Specifically provided is a method for injecting a peptide drug such as insulin, and a device therefor. No special consumables are needed except the drug solution or suspension. The method and device comprise injecting a drug into the living body by electrospraying a solution or suspension of the drug from a nozzle to which high voltage is applied and which is not in contact with the living body.

Abstract: Improvements applied to a textile product, and more particularly wherein the improved product is a woven textile product—fabric containing bioceramic microparticles embedded into the fibers thereof with high capacity of irradiation in the infrared region, provided to be used both in humans and animals, more particularly the invention is related to a textile product containing bioceramic microparticles with high capacity of infrared irradiation which, in contact with the heat of the human body, is capable of transmitting infrared radiation in the range between 3 ?m and 14.8 ?m, preferentially in the 14.8 micron range, said infrared radiation at this wavelength being capable of regulating the blood microcirculation, as the result of its high protection, the blood microcirculation being the nervous center of human and/or animal metabolism.

Abstract: An apparatus comprises one or more physiological sensing circuits that generate a sensed physiological signal and at least one of the physiological sensing circuits is implantable, a measurement circuit configured to recurrently measure one or more physiological parameters that indicate a status of heart failure of the subject, a comparison circuit configured to compare the one or more physiological parameter measurements to one or more physiological parameter target values, a therapy circuit configured to control delivery of one or more drugs to treat heart failure, and a control circuit in electrical communication with the comparison circuit and the therapy circuit and configured to recurrently adjust delivery of drug therapy according to the comparison of the measured physiological parameters to the physiological parameter targets.

Abstract: A kit for treating an antimicrobial resistant biological contaminate at a treatment site is disclosed which includes a diffuser tip adapted to receive near infrared therapeutic light from a light delivery system and diffuse the light to illuminate at least a portion of the treatment site; a quantity of an antimicrobial; agent; instructions to use the antimicrobial agent in conjunction with the therapeutic light to potentiate the antimicrobial agent to treat the biological contaminate, and suitable packaging.

Abstract: Embodiments of the invention provide methods for the transdermal delivery of therapeutic agents for the treatment of addictive cravings e.g., from nicotine. An embodiment of a method for such delivery comprises positioning at least one electrode assembly in electrical communication with a patient's skin. The assembly includes a solution comprising a therapeutic agent which passively diffuses into skin. A dose of agent is delivered from the assembly into skin during a first period using a first current having a characteristic e.g., polarity and magnitude, to repel agent out of the assembly. During a second period, a second current having a characteristic to attract agent is used to retain agent in the assembly such that delivery of agent into skin is minimized. In particular embodiments, a dose of agent may be delivered on-demand using an input from the patient using an inhalation sensing device which mimics an inhaled form of tobacco.

Abstract: An apparatus and method for mineralising demineralised and hypo-mineralised biological material such as tooth or bone. The apparatus has a probe electrode for receiving a mineralisation agent and a counter electrode. It is also provided with a controller to control the electrical signal provided to the probe such that the extent of mineralisation of the biological material is controlled by modulating or changing the electrical signal provided by the probe based upon the measured output of the circuit formed from the probe, counter electrode and biological material. The electrical output provides a measure of the extent of mineralisation of the biological material which is compared with data from a reference technique which gives 3D structural information on an area of interest in the biological material.

Abstract: The present invention provides methods, systems, and devices for performing photothermal therapy (e.g., to treat cancer) using photothermal nanoparticles with a biocompatible coating surrounding a highly crystallized Fe3O4 core. In certain embodiments, the highly crystallized Fe3O4 core of the photothermal nanoparticles has an X-ray diffraction (XRD) pattern where the brightest diffraction ring is from the 440 plane. In some embodiments, the photothermal therapy is conducted with a device configured to emit electromagnetic radiation in the wavelengths between about 650 nm and 1000 nm, wherein the device further comprises a visible light source that allows a user to determine where the electromagnetic radiation is contacting a subject.

Abstract: The present invention is a confocal scanning system for the multispectral imaging of fluorescence from a tissue sample based on the mapping of the spectral components of the fluorescence into the time domain using coated fiber tips disposed on multimode optical fibers. A fiber grating spectrometer based on two serial arrays of coated fiber tips disposed on multi-mode fiber, and delay lines between them provide spectral slices of the florescence. The coated fiber tips are arranged such that the shortest wavelength spectral components are reflected first and the longest wavelength components last. Fiber-based delay lines delay the reflections from each successive fiber tip such that they are uniformly separated in time, and in the order of its spectral wavelength number. The spectral bins are used to colorize the images to show the presence of abnormal tissue at cellular spatial resolution. A second scan with increased laser flux can destroy the diseased tissue revealed by the first scan.

Abstract: The present invention provides pharmaceutical photosensitizer-loaded nanoparticle formulations and their methods of preparation for photodynamic therapy, comprising a hydrophobic or hydrophilic photosensitizer, nanoparticulate calcium phosphate and in certain cases auxiliary reagents such as stabilizers. The calcium phosphate-based nanoparticle formulations of the present invention provide excellent storage stability and therapeutically effective amounts of photosensitizer for intravenous or topical administration. In a preferred embodiment, tetrapyrrole derivatives such as porphyrins, chlorins and bacteriochlorins, are the preferred hydrophobic photosensitizers to be formulated in calcium phosphate nanoparticle formulations for photodynamic tumor therapy. Additionally, 5,10,15,20-tetrakis(4-phosphonooxyphenyl)porphine (pTPPP) is a preferred hydrophilic photosensitizer for photodynamic tumor therapy.

Abstract: An apparatus for the generation of metallic and metal oxide nanoparticles for use in the treatment of periodontal disease has a discharge chamber with a controlled flow of water, the water flowing through a plasma gap formed by electrodes, the electrodes having a pulsed voltage applied to create a plasma discharge, the pulse duration chosen to maximize the generation of nanoparticles from the electrodes which are in the range of 10 nm to 50 nm. The discharge chamber flow rate and pulse duration is controlled to maintain a particular temperature differential across the plasma gap to additionally optimize the nanoparticles population for the desired 10 nm to 20 nm size range having negative surface electric charge. The nanoparticles thereby formed may thereafter be applied to a subject in need thereof as an irrigation treatment, or as a paste applied directly to a region of periodontal disease.

Abstract: The present invention relates to a method for treating a local infection, for example, a periodontal disease, peri-implantitis or dermartitis, comprising applying a composition containing hydrogen peroxide and a polyphenol such as catechins to an infected site, for example, inside oral cavity or skin, and irradiating the site with light for a predetermined period of time.

Abstract: A system comprising a combination of at least one MC1R receptor agonist and a source of NB-UVB, wherein said system is adapted for simultaneous or sequential use of said MC1R receptor agonist and said NB-UVB in amounts effective for the treatment and/or prevention of dermatological conditions linked to a hypopigmentation.

Abstract: Embodiments of the invention provide patch assemblies for iontophoretic transdermal delivery of therapeutic agents. An embodiment provides a patch assembly comprising a conformable patch for delivery of the agent and having a tissue contacting side including an adhesive. The housing has a bottom surface for engaging a non-tissue contacting side of the patch, a current source such as a battery and a controller for controlling the delivery of the agent. The housing has sufficient flexibility such that when it is engaged with the patch to form the patch assembly and the patch is adhered to a target site on the patient's skin, the assembly has sufficient flexibility to deform with movement of the patient's skin to remain sufficiently adhered to the skin over an extended period of time to transdermally deliver a desired dose of the agent. Embodiments of the assembly may used to deliver a variety of therapeutic agents.

Abstract: The present invention provides an infusion-patch comprising; a cannula; a base; at least one adhesive region in said base suitable for skin attachment; at least one skin-access area within said base; and at least one conduit in fluid connection with said at least one skin access area, wherein said at least one conduit in fluid connection with said at least one skin access area facilitates the transfer of an anesthetic substance within at least a first anesthetic-reservoir which may be removably attached and in fluid connection with said at least one contact area, promoting delivery of said anesthetic substance to said at least one skin-access areas, and wherein said anesthetic substance delivered to said skin-access areas may be at least partially replenished without removing said in fusion-patch.

Abstract: Embodiments provide devices, systems and methods for the transdermal delivery of chelated compounds. One embodiment provides a method for the iontophoretic transdermal delivery of a chelated iron complex for the treatment of anemia. A first patch comprising an active electrode and a chelated iron complex is applied to the skin; a second patch containing an electrode is also applied. An electrical current is then delivered to the skin from the active electrode. The chelated complex is transported across the skin via electromotive force from the current, with the iron being substantially chromogenically unreactive with the skin during transport so that there is little or no tattooing of the skin due to the formation of insoluble oxidative products. The complex is then dissociated by phagocytosis or related process to release the iron where it may be bound by transferrin or ferritin and carried to other sites for storage or metabolic use.

Abstract: Devices and methods for therapeutic photodynamic modulation of neural function in a human. One embodiment of a method in accordance with the technology includes administering a photosensitizer to a human, wherein the photosensitizer preferentially accumulates at nerves proximate a blood vessel compared to non-neural tissue of the blood vessel. The method can further include irradiating the photosensitizer using a radiation emitter positioned within the human, wherein the radiation has a wavelength that causes the photosensitizer to react and alter at least a portion of the nerves thereby providing a therapeutic reduction in sympathetic neural activity. Several embodiments of the technology are useful for disrupting renal nerves, such as renal denervation, for treating hypertension, diabetes, congestive heart failure, and other indications.

Abstract: A medical microelectrode includes an elongate electrode body including a tip section, a main body section and, optionally, a coupling section. The tip section, the main body section and, optionally, the coupling section are embedded in a first electrode matrix element, which is substantially rigid, biocompatible and soluble or biodegradable in a body fluid. Additionally the microelectrode includes a dissolution retarding layer on the first electrode matrix element and/or a second electrode matrix element disposed between the first electrode matrix element and the electrode. Upon dissolution or biodegradation of the first electrode matrix element a drug comprised by the first electrode matrix element or the second electrode matrix element is released into the tissue. Also disclosed are bundles and arrays of the electrodes and their use.

Abstract: An iontophoretic dental device that positions electrodes at buccal and lingual gingiva is described herein. The iontophoretic dental device includes an electrode locating member and electrodes that are attached to the electrode locating member. Further described herein is an iontophoretic dental system for simultaneously positioning electrodes at the buccal and lingual gingiva of a tooth on which dental work is performed. The system includes a coupler, lead wires and an iontophoretic dental device that further includes a clamp and electrodes. The electrodes are operatively attached to the clamp. Also described herein is a method of delivering a medicament to teeth or surrounding oral tissues including placing an iontophoretic dental device on buccal and lingual gingiva, the device including a clamp, and applying current to the electrodes.

Abstract: Chronic sinusitis is treated by the application of cold plasma or plasma-activated species to the infected mucosal surfaces through use of an endoscope having a steerable end which may be projected into the sinus cavities through the nasal cavity. The cold plasma is generated at either the distal end of the endoscope with a power source by application of a power, or at the distal end by gas and electrical connections extending through the endoscope. The cold plasma or plasma-activated species act to destroy bacterial cells but not eukaryotic cells.

Abstract: The present invention relates generally to transscleral, transcorneal, and transocular delivery of biologically active substances through the tissues, blood vessels and cellular membranes of the eyes of patients without causing damage to the cellular surface, tissue or membrane. The invention provides compositions and methods for enhanced transscleral, transcorneal and transocular delivery of biologically active substances using pulsed incoherent light, and particularly the transcleral, transcorneal or transocular delivery of high molecular weight biologically active substances to a patient using pulsed incoherent light. The invention further provides a device for the application of the pulsed incoherent light to cellular surfaces and membranes of the eye of a subject using those compositions and methods.

Abstract: The present invention describes Photolabile Compounds methods for use of the compounds. The Photolabile Compounds have a photoreleasable ligand, which can be biologically active, and which is photoreleased from the compound upon exposure to light. In some embodiments, the Photolabile Compounds comprise a light antenna, such as a labeling molecule or an active derivative thereof. In one embodiment, the light is visible light, which is not detrimental to the viability of biological samples, such as cells and tissues, in which the released organic molecule is bioactive and can have a therapeutic effect. In another embodiment, the photoreleasable ligand can be a labeling molecule, such as a fluorescent molecule.

Abstract: This invention relates to modified nucleic acid compositions encoding therapeutic polypeptides and methods of producing the therapeutic polypeptides in cells.

Abstract: Methods and compositions to controllably regulate cells at a target site. A quantum dot-targeting agent complex is administered to a patient in need of therapy, and the complex is stimulated using an implanted fiber optic system. In embodiments, the system includes an electrical sensor that detects and monitors electrical activity of the stimulated controllably regulated cells, and relays this information to a controller that can regulate further stimulation.

Abstract: An active transdermal medicament patch includes a planar substrate with a therapeutic face releasably retainable against the skin of a patient. A return electrode and a medicament matrix susceptible to permeation by medicament are secured at separated locations on the therapeutic face and electrically conductively engage the skin. A detector monitors iontophoretic medicament migration into the skin. An integrator operating on the output of the detector produces a running cumulative total of the amount of medicament delivered during a plurality of temporally non-contiguous therapy subsessions. A circuit breaker terminates medicament migration, when the output of the integrator equals a predetermined medicament quantity. A timer active during medicament migration stimulates a driver to operate a light-emitting diode in a distinct delivery confirmation mode during each a sequence of non-overlapping predetermined therapy subsessions, respectively.

Abstract: A spinal cord stimulator lead for implanting into the epidural space of a human or animal subject includes first and second lumens and electrical contacts. A pressurized fluid can be discharged through the first lumen directly onto a tissue obstruction to form a partial/pilot or full/final opening in the tissue obstruction. If a full opening was not formed sufficient for passage of the stimulator lead, the distal-end portion of the stimulator lead can be inserted into the partial opening and then a pressurized fluid can be delivered through the second lumen and into a distensible balloon for expanding the balloon to clear the tissue obstruction sufficient for passage of the stimulator lead. In this way the stimulator lead can be advanced past a tissue obstruction and into place for use to deliver therapeutic energy to spinal tissue adjacent the contacts, without having to remove and reinsert multiple surgical implements.

Abstract: Systems and methods are disclosed herein for prophylactic application of near-infrared optical energies and dosimetries to photo-biologically inhibit accelerations or intensifications in biofilm production, after a bacterial or fungal pathogen is challenged with an antibiotic or antifungal agent. This photo-biologic minimum biofilm inhibitory concentration (PMBIC) of infrared light will lower the minimum inhibitory concentration (MIC) necessary of an antibiotic and/or antifungal molecule necessary to decrease bacterial and fungal pathogens in human tissues. These systems and methods will only target undesirable microbial cells.

Abstract: Embodiments apply a cross-linking agent to a region of corneal tissue. The cross-linking agent improves the ability of the corneal tissue to resist undesired structural changes. For example, the cross-linking agent may be Riboflavin or Rose Bengal, and the initiating element may be photoactivating light, such as ultraviolet (UV) light. In these embodiments, the photoactivating light initiates cross-linking activity by irradiating the applied cross-linking agent to release reactive oxygen radicals in the corneal tissue. The cross-linking agent acts as a sensitizer to convert O2 into singlet oxygen which causes cross-linking within the corneal tissue. The rate of cross-linking in the cornea is related to the concentration of O2 present when the cross-linking agent is irradiated with photoactivating light. Accordingly, the embodiments control the concentration of O2 during irradiation to increase or decrease the rate of cross-linking and achieve a desired amount of cross-linking.

Abstract: The invention relates to transdermal compositions including nifedipine, pentoxifylline, ketamine hydrochloride, gabapentin, lidocaine, and prilocaine that may be used to treat conditions such as circulatory disorders and peripheral neuropathy. Additionally, methods of the invention are directed to treating conditions such as circulatory disorders, peripheral neuropathy, wound healing, blood flow issues, or the like, comprising the steps of transdermal or topical administration of the compositions.

Abstract: Photodynamic devices for stabilizing a joint are provided. In some embodiments, a photodynamic joint spacer is provided that includes an expandable member configured for attachment to a bone having an excised region; a formable bar configured for attachment to the bone along at least a portion of the expandable member; and a light-sensitive liquid passed into the expandable member to expand the expandable member, wherein the expandable member is shaped by the formable bar to a shape resembling the excised region of the bone, and wherein the light-sensitive liquid is curable upon exposure to light energy to set the expandable member in the shape resembling the excised region to form a photodynamic joint spacer.

Abstract: A method and device for photodynamic therapy for treating cancer. The method includes: providing a photodynamic therapeutic device for treating cancer. The provided device includes a plurality of light emitting diodes that are positionable in proximity of a patient's body and are adapted to provide a light fluence to a lesion area. The method also includes administering an effective dose of a photosensitizer in the lesion area; positioning the device in proximity to the patient's body; and irradiating the patient's body.

Abstract: As the percentage of senior citizens increases at the present time, the purpose of the present invention is to provide a cosmetic which can maintain the skin in a healthy state by preventing damage to the skin that accompanies aging, more specifically, discoloration and wrinkling, is very safe, does not pose ethical problems, and can be supplied in a sufficient amount. The present invention provides a cosmetic that comprises as the main component a powder of the supernatant produced by culturing the bone marrow or dental pulp stem cells of a nonhuman mammal. Moreover, provided is a method for ion introduction for protein by which the cosmetic is introduced by ion introduction.

Abstract: A transdermal device (1) comprising at least one substrate (2) arranged to be applied against the dermal surface or the mucous membrane. The at least one active ingredient is grafted to the substrate (2) by at least one photolabile ligand, and at least one light source (11) operated by a control mechanism arranged to generate light pulses, of a predetermined wavelength, intended to break covalent bonds between the active ingredient and the ligand in order to release the active ingredient from the substrate (2). The substrate (2) comprises at least one porous matrix (6) with a three-dimensional structure comprising a plurality of pits (7) organized in a sponge-like fashion and constructed of a polymer chosen between chitin and chitosan, and the matrix (6) defines at least one three-dimensional tank (8). The active ingredient is contained and grafted by the ligand.

Abstract: The present invention relates to the use of an inhibitor of HER-3 for the treatment of a hyperproliferative disease in combination with radiation treatment.

Abstract: A delivery system, including: a material for storing molecules and/or nanoparticles by substantially binding said molecules and/or nanoparticles to said material; a means for applying an electric field to said material to release said molecules and/or nanoparticles; and a means for applying an ultrasonic signal to said material to transport said molecules and/or nanoparticles through said material to a surface for delivery to an entity.

Abstract: The present invention relates generally to therapeutic compositions comprising chitosan-derived compositions used in connection with methods for treating neoplasms, such as for instance, malignant lung, thyroid and kidney neoplasms, and other types of malignant neoplasms, and other medical disorders.

Abstract: Methods, devices, kits and compositions to treat a myocardial infarction. In one embodiment, the method includes the prevention of remodeling of the infarct zone of the ventricle using a combination of therapies. The method may include the introduction of structurally reinforcing agents. In other embodiments, agents may be introduced into a ventricle to increase compliance of the ventricle. The prevention of remodeling may include the prevention of thinning of the ventricular infarct zone. Another embodiment includes the reversing or prevention of ventricular remodeling with electro-stimulatory therapy. The unloading of the stressed myocardium over time effects reversal of undesirable ventricular remodeling. These therapies may be combined with structurally reinforcing therapies. In other embodiments, the structurally reinforcing component may be accompanied by other therapeutic agents. These agents may include but are not limited to pro-fibroblastic and angiogenic agents.

Abstract: Methods and devices related to the treatment of diseases using phototherapy are described. Some embodiments provide an organic light-emitting diode device, such as a light-emitting device for phototherapy, comprising Ring system 1, Ring system 2, Ring system 3, or Ring system 4. Methods of treating disease with phototherapy are also described.

Abstract: A device, a system, or a method is described for treating a disease or a condition of one or more joints of articulating bone in a mammalian subject. The device provides one or more medicaments to one or more joints of the mammalian subject. A device is described that includes one or more substrates configured to contact one or more body contours in proximity to one or more joints of articulating bone of a mammalian subject; one or more sensors configured to monitor movement of the one or more body contours; and one or more applicators supported by the one or more substrates and configured to respond to the movement of the one or more body contours by injecting one or more medicaments to the one or more joint tissues of the mammalian subject.

Abstract: A system for treatment of tumors includes a vessel having a photosensitizing agent therein, a delivery device for communicating the photosensitizing agent from the vessel to tumor tissue, a light source for radiating the tumor tissue after the delivery device has delivered the photosensitizing agent to the tumor tissue, a catheter having at least one inflatable balloon positioned thereon, and a fluid source that repeatedly inflates and at least partially deflates the inflatable balloon such that a resecting outer surface of the balloon contacts the radiated tumor tissue and resects the tissue.

Abstract: Treatment of skin tissue with photoactive materials and light, such as nanoparticles and formulations which are useful for cosmetic, diagnostic and therapeutic applications to mammals such as humans. In particular, embodiments of thermal treatment of a pilosebaceous unit with metal nanoparticles in surfactant containing solutions are disclosed.

Abstract: The present invention concerns a device for treatment of a wound by attachment to the skin, comprising a set of electrodes arranged on a carrier member and connected to an electrical power source having a first and a second terminal which are connected to each of the electrodes, wherein the set of electrodes comprises two non-interconnected electrically conducting wires arranged in a pattern on said carrier member and that the electrically conducting wires are provided with an irregular surface structure.

Abstract: A method of treating mammalian skin tissues for causing a predetermined physiological change in the mammalian skin tissues. A treatment composition of matter is applied onto the mammalian skin. The mammalian skin is irradiated with a first pulse having a power density above an activation threshold power density and with a second pulse. The first pulse is emitted for a duration of from about 1 femtosecond to about 1 hour, and the first pulse is separated from the second pulse by an inter-pulse interval of from about 1 microsecond to about 10 seconds. The treatment composition of matter includes a photoreactive substance and is applied in an amount sufficient to cause physiological changes within the mammalian skin tissue upon the mammalian skin tissue being irradiated.

Abstract: A contact electrode assembly for delivering at least one therapeutic agent into ocular tissue of a subject includes a flexible dielectric layer, a first electrode portion, and a second electrode portion. The flexible dielectric includes oppositely disposed first and second surfaces. The first electrode portion is disposed on the first surface of the dielectric layer. The second electrode portion is disposed on a portion of the second surface of the dielectric layer. The second electrode portion includes an interdigitated electrode having a first comb-shaped portion defining a first plurality of fingers and a second comb-shaped portion defining a second plurality of fingers. Each of the first electrode portion, the first comb-shaped portion, and the second comb-shaped portion is electrically connectable to a signal source.

Abstract: A skin treatment device includes a handle and a tip, having a skin applying surface, detachably coupled to the handle. A fluid delivery structure is formed at skin applying surface and has an aperture and a vacuum entry port. A fluid detouring path is defined between the aperture and the vacuum entry port for prolonging a traveling path of fluid from the aperture and the vacuum entry port. An abrading structure, an electrode structure, and a micro-needling structure are selectively provided at the skin applying surface with the fluid delivery structure to provide multiple functions of the tip.

Abstract: A method for delivering liquid into the pores of recipient human skin is provided. The method comprises delivering, via a nozzle, at least one stream of the liquid under pressure to the pores, the stream having a cross-section with a diameter no greater than about 50 ?m, applying a negative pressure across an area of the skin being treated, rotating the nozzle relative to the area at a speed up to about 200 revolutions per minute, contacting an electrode connected to a first terminal of a power source, having a first electric charge, to the skin, and contacting a second terminal of the power source, having a second electric charge, opposite the first electric charge, to the liquid, thereby imparting an electrical current between about 0.2 mA and 0.3 mA to the skin in the vicinity of the pores. The delivering, applying, rotating, and contactings occur simultaneously.